Tumors Originating from Induced Pluripotent Stem Cells and Methods for Their Prevention

Pluripotent stem cells represent an almost unlimited source of most somatic cell types, providing them with great potential for cell‐based therapies. The earliest methods used for generating human pluripotent stem cells as embryonic stem cells from human embryos suffered from ethical and technical d...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2009-09, Vol.1176 (1), p.197-204
Main Authors: Duinsbergen, Dirk, Salvatori, Daniela, Eriksson, Malin, Mikkers, Harald
Format: Article
Language:English
Subjects:
Animals
Cell Culture Techniques
Embryos
Ethics
Formations
Gene Transfer Techniques
Human
Humans
iPS cell
Lentivirus - genetics
Mice
Neurons - physiology
pluripotency
Pluripotent Stem Cells - pathology
Pluripotent Stem Cells - physiology
reprogramming
rhabdomyosarcoma
Rhabdomyosarcoma - pathology
Rhabdomyosarcoma - prevention & control
Rhabdomyosarcoma - virology
State of the art
Stem Cell Transplantation - adverse effects
Stem cells
Therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pluripotent stem cells represent an almost unlimited source of most somatic cell types, providing them with great potential for cell‐based therapies. The earliest methods used for generating human pluripotent stem cells as embryonic stem cells from human embryos suffered from ethical and technical drawbacks. These problems have been solved in part through the efficient induction of pluripotency in somatic cells using forced expression of a tetrad of factors. Here, we describe the formation of rhabdomyosarcomas originating from factor‐induced pluripotent stem (iPS) cells derived from mouse neural stem cells. This underscores the commonly accepted notion that the use of retroviral delivery methods for inducing pluripotency will not be suited for clinical applications. However, the iPS cell field is developing rapidly. Safer protocols are now available for producing pluripotent stem cells. Here the current state‐of‐the‐art in this field will be discussed.
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.2009.04563.x